Evidence map›Paper›PMID 29055813›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2018

Amyloid β synaptotoxicity is Wnt-PCP dependent and blocked by fasudil.

Katherine J Sellers, Christina Elliott, Joshua Jackson, Anshua Ghosh, Elena Ribe, Ana I Rojo, Heledd H Jarosz-Griffiths, Iain A Watson, Weiming Xia, Mikhail Semenov and 12 more

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06362707 (A Placebo Controlled Randomized Double-blind Parallel Group 12-month Trial of Fasudil for the Treatment of Early Alzheimer's Disease), which is not on this map. Cited by 63 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06362707 phase2recruitingnot on this mapstarted 2024, after this paper: background citation

A Placebo Controlled Randomized Double-blind Parallel Group 12-month Trial of Fasudil for the Treatment of Early Alzheimer's Disease (FEAD)

TypeinterventionalSponsorHelse Stavanger HFRan2024 to 2028Enrolled200ConditionsCognitive Decline, Mild, Alzheimer DiseaseArmsFasudil, Placebo
3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 1 synthesis or guideline pooled it, 105 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Amyloid Beta Oligomers as Early Triggers of Neuronal Cytoskeleton Dysfunction in Alzheimer's Disease.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Wnt/β-catenin Signaling in Central Nervous System Regeneration.Advances in experimental medicine and biology · 2025
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 13 institutions in 3 countries.

Katherine J SellersKing's College London, Maurice Wohl Clinical Neuroscience Institute, London, UK.
Christina ElliottKing's College London, Maurice Wohl Clinical Neuroscience Institute, London, UK.
Joshua JacksonThe University of Manchester, Faculty of Biology, Medicine and Health, Division of Pharmacy and Optometry, Manchester, UK.
Anshua GhoshKing's College London, Maurice Wohl Clinical Neuroscience Institute, London, UK.
Elena RibeUniversity of Oxford, Department of Psychiatry, Warneford Hospital, Oxford, UK.
Ana I RojoCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED). Instituto de Investigación Sanitaria La Paz (IdiPaz), Autonomous University of Madrid, Madrid, Spain.
Heledd H Jarosz-GriffithsThe University of Manchester, Faculty of Biology, Medicine and Health, Division of Neuroscience and Experimental Psychology, Manchester, UK.
Iain A WatsonKing's College London, Maurice Wohl Clinical Neuroscience Institute, London, UK.
Weiming XiaBoston University School of Medicine, New England Geriatric Research Education and Clinical Center, Boston, USA.
Mikhail SemenovBoston University School of Medicine, New England Geriatric Research Education and Clinical Center, Boston, USA.
Peter MorinBoston University School of Medicine, New England Geriatric Research Education and Clinical Center, Boston, USA.
Nigel M HooperThe University of Manchester, Faculty of Biology, Medicine and Health, Division of Neuroscience and Experimental Psychology, Manchester, UK.
Rod PorterRod Porter, Rod Porter Consultancy, Baldock, England, UK.
Jane PrestonKing's College London, Institute of Pharmaceutical Science, Franklin-Wilkins Building, London, UK.
Raya Al-ShawiUniversity College London, Centre for Amyloidosis and Acute Phase Proteins, Royal Free Campus, London, UK.
George BaillieUniversity of Glasgow, Institute of Cardiovascular and Medical Science, Glasgow, Scotland.
Simon LovestoneUniversity of Oxford, Department of Psychiatry, Warneford Hospital, Oxford, UK.
Antonio CuadradoCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED). Instituto de Investigación Sanitaria La Paz (IdiPaz), Autonomous University of Madrid, Madrid, Spain.
Michael HarteThe University of Manchester, Faculty of Biology, Medicine and Health, Division of Pharmacy and Optometry, Manchester, UK.
Paul SimonsUniversity College London, Centre for Amyloidosis and Acute Phase Proteins, Royal Free Campus, London, UK.
Deepak P SrivastavaKing's College London, Maurice Wohl Clinical Neuroscience Institute, London, UK. Electronic address: Deepak.Srivastava@kcl.ac.uk.
Richard KillickKing's College London, Maurice Wohl Clinical Neuroscience Institute, London, UK. Electronic address: Richard.1.Killick@kcl.ac.uk.
King's College London · GBManchester Academic Health Science Centre · GBGeriatric Research Education and Clinical Center · USBiomedical Research Networking Center on Neurodegenerative Diseases · ESBoston University · USPorter Brook Medical Centre · GBThe Royal Free Hospital · GBUniversidad Autónoma de Madrid · ESUniversity College London · GBUniversity of Glasgow · GBUniversity of Manchester · GBUniversity of Oxford · GBWarneford Hospital · GB

Funding

Medical Research Council MR/J007412/1Medical Research Council MR/L021064/1Medical Research Council MR/M013944/1Medical Research Council MR/N026063/1
6 · The paper itself

Abstract

introductionSynapse loss is the structural correlate of the cognitive decline indicative of dementia. In the brains of Alzheimer's disease sufferers, amyloid β (Aβ) peptides aggregate to form senile plaques but as soluble peptides are toxic to synapses. We previously demonstrated that Aβ induces Dickkopf-1 (Dkk1), which in turn activates the Wnt-planar cell polarity (Wnt-PCP) pathway to drive tau pathology and neuronal death.

methodsWe compared the effects of Aβ and of Dkk1 on synapse morphology and memory impairment while inhibiting or silencing key elements of the Wnt-PCP pathway.

resultsWe demonstrate that Aβ synaptotoxicity is also Dkk1 and Wnt-PCP dependent, mediated by the arm of Wnt-PCP regulating actin cytoskeletal dynamics via Daam1, RhoA and ROCK, and can be blocked by the drug fasudil. DISCUSSION: Our data add to the importance of aberrant Wnt signaling in Alzheimer's disease neuropathology and indicate that fasudil could be repurposed as a treatment for the disease.

Indexed as

Wnt Signaling Pathway1-(5-Isoquinolinesulfonyl)-2-MethylpiperazineAmyloid beta-PeptidesAnimalsCells, CulturedCerebral CortexDose-Response Relationship, DrugFemaleIntercellular Signaling Peptides and ProteinsMaleMiceNeuroprotective AgentsNootropic AgentsPrimary Cell CultureRatsRNA, Messenger1-(5-Isoquinolinesulfonyl)-2-MethylpiperazineAmyloid beta-PeptidesfasudilIntercellular Signaling Peptides and ProteinsNeuroprotective AgentsNootropic AgentsRNA, MessengerAlzheimer's diseaseAmyloidDAAM1Dickkopf-1FasudilPlanar cell polarityROCKSynapseSynaptotoxicityWnt

Identifiers

PMID29055813
PMCPMC5869054
OpenAlexW2766446922

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.